Lung Cancer
-
Study evaluates amivantamab plus lazertinib for EGFR-mutant NSCLC with CNS metastases
With the combination now available, Mark Jeng, MD, PhD, revisits positive results from a recent study evaluating the strategy in this high-risk population.
-
Putting radon on your clinical radar
Hear from Clifford Mitchell, MD, MPH, Director of the Environmental Health Bureau at the Maryland Department of Health, about when to test, who is most at risk, and why clinicians should make radon awareness part of routine care.
-
First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC
Brett Bade, MD, and Katie Smith, MD, said the expansion of targeted therapies for lung cancer is an important advance, while noting that questions remain regarding the drug’s role in the first-line setting.
-
How social determinants of health impact lung cancer care
Patient outcomes in lung cancer care vary greatly by race, geography, income, and access to care. Learn how experts are addressing disparities through education, screening, and culturally responsive and personalized care.
-
Setidegrasib demonstrates durable responses in KRAS G12D-mutant NSCLC
Coauthor Anup Kasi, MD, MPH, said the study represents an important step forward in the development of KRAS G12D-targeted therapies.
-
The evolution of interventional pulmonology
Interventional pulmonology has rapidly evolved into a technology-driven specialty, with advances like robotic bronchoscopy and real-time imaging enabling safer, more precise access to peripheral lung lesions. These innovations allow clinicians to combine diagnostic and therapeutic procedures in a single setting.
-
Link between viral pneumonia, lung cancer risk underlies importance of vaccination against respiratory infections
New data add weight to the case for protecting against respiratory viruses as part of lung cancer prevention.
-
Real-world data show adherence to nodal dissection standard improves detection of lymph node involvement in patients with NSCLC
Increased lymph node analysis was associated with a 2.1% absolute increase in pathologic nodal upstaging, according to recent research.
-
AI-enabled approaches poised to transform diagnosis, management of lung diseases
Experts explore how AI-based tools can be used to bridge diagnostic challenges and address unmet needs in chronic respiratory disease care.
-
AI tools like Sybil poised to improve lung cancer screening, risk prediction
The Sybil model has shown promising results in predicting lung cancer risk in diverse populations from a single CT scan, which could address gaps and disparities in current screening guidelines.
